Highlights SanBio Company Limited

Equities

4592

JP3336750009

Market Closed - Japan Exchange Other stock markets 11:30:00 26/06/2024 am IST			5-day change	1st Jan Change
1,098 ^JPY	+15.82%		+10.02%	+56.41%

20/06	SanBio Awaits Official Approval for Brain Injury Treatment Candidate After Positive Deliberation by Regulatory Subcommittee	MT
17/06	SanBio’s Attributable Losses Narrows in Fiscal Three Months	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SanBio Awaits Official Approval for Brain Injury Treatment Candidate After Positive Deliberation by Regulatory Subcommittee	20/06	MT
SanBio’s Attributable Losses Narrows in Fiscal Three Months	17/06	MT
SanBio Company Limited Announces Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan	12/06	CI
SanBio Books Non-operating Income, Extraordinary Gains, Deferred Income Taxes in Fiscal 2024	19/03	MT
SanBio's FY2024 Attributable Net Loss Narrows on Lower Costs, Forex Gains	19/03	MT
Sanbio Company Limited Provides Consolidated Earnings Guidance for the First Half of Fiscal Year Ending January 31, 2025, and Full Fiscal Year Ending January 31, 2025	18/03	CI
Sanbio Co., Ltd. Provides Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan	25/01	CI
SanBio to Cancel Certain Stock Options	10/01	MT
SanBio Logs Extraordinary Gain from Asset Sale of US Unit	21/12	MT
Sanbio Widens Nine-Month Attributable Net Loss	15/12	MT
Sanbio Expects to Receive Regulatory Nod for Stem Cell Therapy Candidate in March 2024	15/12	MT
SanBio Company Limited Provides Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury Program in Japan	14/12	CI
SanBio Co., Ltd. Updates on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury Program in Japan	14/23/14	CI
SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year Ending January 31, 2024	14/23/14	CI
SanBio's FY23 Loss Widens	20/23/20	MT
Sanbio Company Limited Provides Consolidated Earnings Guidance for the First Half of Fiscal Year Ending January 31, 2024, and Full Fiscal Year Ending January 31, 2024	17/23/17	CI
SanBio to Acquire, Cancel Over 100,000 Stock Options	23/23/23	MT
SanBio Shares Rise 3% on Establishment of In-House Facility for Packaging, Storage of Regenerative Medicines	22/22/22	MT
SanBio Company Limited Announces Establishment of In-House Facility and Acquisition of License for Packaging, Labeling and Storage of Regenerative Medicine Products	21/22/21	CI
SanBio Posts Narrowed FY23 Nine-month Loss on Foreign Exchange Gains, Lower Expenses	16/22/16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SanBio Company Limited

Equities

4592

JP3336750009

Highlights

Filters